Acquisition / mergerFiled on BSE ·
Aurobindo Pharma subsidiary Apitoria completes acquisition of A1 Biochem Group business
Aurobindo Pharma · Pharmaceuticals & Biotechnology
What the filing says
- Apitoria Pharma, a wholly owned subsidiary of Aurobindo Pharma, acquired the Contract Research Services business of A1 Biochem Group.
- Apitoria now holds 80% ownership in A1 Biochem Labs India Pvt Ltd; 20% is held by Dr. Rajendra Gadikota.
- Through A1 Labs India and its subsidiaries in the USA, Apitoria gains access to a CRO platform with 50+ clients and 800+ completed projects.
Original filing
Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations, 2015.
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Waaree Energies
Electrical Equipment
Revenue growth 40%+Margin up 2%+
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Other acquisition / merger filings this fortnight
- Acquisition / mergerMonolithisch India LtdMonolithisch India Limited investor call transcript dated September 30, 2026
- Acquisition / mergerHindustan Aeronautics LtdHindustan Aeronautics Ltd acquires 50% stake in HATSOFF Helicopter Training Pvt. Ltd
- Acquisition / mergerSahana Systems LtdSahana Defence Limited to acquire 60% stake in Siddhanta Machining Pvt Ltd
- Acquisition / mergerSahana Systems LtdSahana Defence Limited to acquire 60% stake in Siddhanta Machining Pvt Ltd
- Acquisition / mergerIndo Borax & Chemicals LtdIndo Borax acquires 64.26% stake in Kronox Lab Sciences and appoints new MD & CEO
- Acquisition / mergerJagsonpal Pharmaceuticals LtdJagsonpal Pharmaceuticals acquires Wellness Portfolio of Group Pharmaceuticals Ltd on Oct 1, 2026
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.